



**30%**

Increase cost of  
care

**x5**

more likely to receive  
delayed care

**€4B/**

year without  
salaries



## AUTONOMOUS PRIORITIZATION

Continuous monitoring and patients  
triage with real-world data and  
**wearable biosensors**




## NOTIFICATION SYSTEM

Notify healthcare personnel  
**when** health deterioration  
occurs and **where** patients are  
located



## BUSINESS INTELLIGENCE


**Continuous predictions** on a)  
hospitalization need, b) length of  
stay, c) admission in the ICU and  
**localization analysis**



## Current practice



- ✓ Not safe to make diagnosis
- ✓ Waiting for the medical exams results to act
- ✓ Valuable time is lost
- ✓ Worse health and economic outcomes



## While using EMMA



- ✓ Early signs of health deterioration are extracted
- ✓ EMMA notifies that they should not wait any longer
- ✓ **ACT NOW**



- 635k€ in research grants
- 250k€ early investment
- Patent-pending technology
- Accepted from Health Founders accelerator, Tallin
- Funded by EIT Health

2 active  
pilots

creating  
traction of 100  
patients/month

€2.4b

TOTAL EU MARKET


€610m

ADDRESSABLE  
MARKET

UK 1.257 NHS  
HOSPITALS

GERMANY 1.239  
HOSPITALS

POLAND 1.236  
HOSPITALS



€550k



CE Certification



Paying customers



€60m

2023


2024

2026



2028

# Why EMMA?

Co-designed along with EMMA's users (doctors) and customers (healthcare decision makers) from concept inception to MVP







# Find us on **emmatriage.com**

Ülemiste City, Valukoja 7  
11415, Tallinn, Estonia

[alexis.fourlis@emmatriage.com](mailto:alexis.fourlis@emmatriage.com)

---

**EMMA's R&D**  
10km Thessaloniki – N.Moudania av.  
57001, Thessaloniki, Greece